← Back to Market Calendar · AI SW/Semi List → · H2 Sector Outlook → · δΈ­ζ–‡

AI-Involved Bio & Drug Company List — 2026-07-02

Snapshot date 2026-07-02. Companion to ai_companies_layered_2026_06_29 (SW/Semi) — this file covers healthcare exposure to the AI theme.
Trigger prompt: "Similar to the previous AI SW/Semi analysis, please analyze AI-benefiting Bio/Drug stocks."
All 6M / 1Y / valuation numbers are 2026-07-02 close. Re-verify before sizing — this is a research snapshot, not live data. AI-benefit tier is qualitative (based on public AI R&D positioning), not quantitative.
Structural read: Semi + SW is where AI is being built; Bio/Drug is where AI will be applied. The bio side is much earlier in its AI rally cycle. Many pure AI-native biotech names are still small/mid cap and have already surged; large pharma has BARELY started to price in AI-drug-discovery productivity gains. The biggest asymmetry: ILMN + GH + NTRA + TEM in AI diagnostics, and MRNA in AI-native mRNA design. Life-sciences tools (TMO / DHR / VEEV / ISRG) sold off in H1 2026 — setup mirrors the "AI beaten-down SW" thesis (Tier 2 in the H2 outlook).

🧬 Tier 1 — AI-Native Drug Discovery (Pure-Play, Small/Mid Cap)

Companies whose entire platform is AI/ML-driven drug design. Highest upside if AI-in-pharma delivers, highest wipeout risk if it doesn't. Small caps → size positions.

TkrMktCapPrice6M1Y%52WAI Role
MRNA ⭐⭐$28.8B$72.50+133%+153%98%AI-native mRNA sequence design + rapid vaccine iteration — the platform IS the AI
ABSI ⭐⭐$1.9B$11.11+222%+329%90%Generative AI antibody design (de novo) — deals with AstraZeneca / Almirall
ABCL ⭐$2.3B$7.60+120%+118%86%AI antibody discovery platform — deals with Regeneron / Pfizer / Moderna
CDXS$0.2B$2.39+46%−0.4%49%AI-enzyme engineering — Novartis / Merck / Codexis Performance
SDGR$1.2B$16.39−8%−21%43%Physics-based computational drug design (older AI stack, needs re-rating)
RXRX$1.9B$3.67−11%−29%20%Cell-image AI drug discovery — NVDA partner but stock struggling
NAUT$0.2B$1.84−5%+152%33%AI single-molecule proteomics — too speculative, watch only

πŸ₯ Tier 2 — Big Pharma with AI Drug Programs

Mega-cap pharma that has made explicit AI-drug-discovery / AI-trial-design commitments. Rally in this tier lags because the market treats these as "old pharma"; catch-up trade if AI narrative extends beyond semis.

TkrMktCapPE/FPEPEG6M1Y%52WAI Role
LLY ⭐$1.12T43/270.94+10.5%+54%92%AI drug discovery + GLP-1 — largest pharma cap-weighted AI story
MRK$310B35/132.17+17.6%+53%91%AI clinical trial optimization + oncology pipeline (Keytruda succession)
JNJ$611B29/202.19+22.4%+63%94%AI in diagnostics + medtech; steady mega-cap AI-adjacent
AMGN$195B25/154.21+9.6%+24%75%AI antibody + obesity pipeline; deals with Xaira / Verge
NVS$282B22/162.55+10.7%+25%72%AI drug discovery (Isomorphic Labs partner)
AZN$285B28/161.29−1.7%+32%63%Absci partnership + oncology AI — lagging cell, catch-up candidate
BIIB$31B23/132.06+18.6%+61%90%Alzheimer's AI biomarker + neuro pipeline
BMY$115B16/9—+4.3%+19%68%Modest AI programs; value play with hair on it
GILD$156B17/131.44+0.9%+13%37%HIV + oncology; AI-adjacent only
GSK$103B13/101.85+4.5%+32%60%AI partnerships (23andMe data + Google DeepMind); value pharma
VRTX$126B30/232.14+8.3%+10%93%CF + gene-editing partnerships; premium bio, limited AI narrative
REGN$65B15/121.02−20%+17%35%Deep drawdown — Eylea competition; AbCellera partner but story hurt
PFE$136B18/8—−4.5%−5%14%Post-COVID reset; AI programs exist but story dominated by Seagen digestion

πŸ”¬ Tier 3 — AI Diagnostics & Precision Medicine

Where AI is already generating alpha. These names have surged as the AI-in-medicine narrative developed independently of drug pipelines. Highest-conviction Bio/Drug AI tier by track record.

TkrMktCapPE/FPE6M1Y%52WAI Role
TWST ⭐⭐$6.4B—+211%+178%98%AI-designed synthetic DNA for drug discovery — picks-and-shovels of AI bio
GH ⭐⭐$22.6B—+68%+237%115%Guardant — AI liquid biopsy oncology; multi-cancer early detection
ILMN ⭐$27.8B33/31+37%+87%101%AI genomic interpretation on NGS platform; DRAGEN pipeline
NTRA ⭐$39.6B—+19%+72%101%Natera — AI prenatal + oncology / transplant testing
TEM ⭐$11.1B—+0.2%+3.6%32%Tempus AI — the "Palantir of oncology"; enterprise AI + clinical data
CDNA$1.5B—/26+52%+55%98%CareDx — AI transplant diagnostics
ADPT$3.6B—+34%+100%106%Adaptive Bio — AI immune profiling
CRSP$5.4B—+3%+15%33%CRISPR — AI-in-target-ID adjacent; gene-editing hedge
PACB$0.5B—+2%+35%40%PacBio — long-read sequencing; struggling but AI-adjacent

πŸ›  Tier 4 — AI-Enabled Life-Sciences Tools & CROs (Beaten Down)

The "AI SW deep-discount" analog of the bio world. AI is being embedded in trial design / lab automation / life-sciences CRM, but names sold off 15-30% in H1 2026. If AI-in-pharma narrative catches up, this tier catches a bid.

TkrMktCapPE/FPEPEG6M1Y%52WAI Role
VEEV$29.9B33/181.55−18%−35%22%Life-sciences CRM + AI clinical-trial mgmt — deep discount
IQV$33.9B25/141.48−10.5%+25%53%AI clinical-trial services + real-world evidence platform
TMO$190.8B28/191.99−12%+22%46%Life-sciences tools mega-cap; AI in lab automation
DHR$137.1B37/212.50−16%−4%40%Danaher — life-sciences tools + Beckman Coulter diagnostics AI
A$37.7B27/202.16−3%+11%48%Agilent — AI-in-mass-spec / chromatography analytics
MEDP$15.5B34/292.70−5%+69%74%Medpace — premium CRO; AI trial optimization
ICLR$13.4B81/156.32−4%+18%75%Icon — CRO, AI trial services

πŸ€– Tier 5 — AI-Assisted Medtech (Deep Drawdown Watch)

Medtech that overlaps with AI (surgical robotics, cardiac AI, imaging AI). All three names are in deep drawdown — NOT a rally-catch-up tier yet, but worth monitoring for stabilization.

TkrMktCapPE/FPE6M1Y%52WAI Role
ISRG$142.5B49/34−30%−25%3%Intuitive Surgical — AI-assisted surgical robotics; sold off hard
ABT$160.6B26/15−26%−32%18%Abbott — diabetes CGM + diagnostics AI
MDT$101.4B21/12−18%−11%18%Medtronic — AI surgical navigation + cardiac AI

⚠️ Explicit Avoids / Not-AI

Excluded (weak AI narrative or single-name issues): SNY (limited AI) · TAK (limited AI) · HIMS (consumer telehealth, not core AI drug) · TDOC (consumer telehealth, AI-adjacent only) · HALO (specialty) · SHC (sterilization) · SNPS (already covered as AI SW/Semi enabler)

Key Judgment

  1. MRNA is the standout AI-in-biotech mega-cap. Only AI-native platform at >$25B cap with 6M +133%. Runner: LLY, MRK, JNJ in big pharma with material AI programs β€” those are catch-up trades not surges.
  2. Tier 3 AI Diagnostics is where alpha has already been booked. TWST +211%, GH +68%, ILMN +37%, ABSI +222%, ABCL +120%. Rerun risk is real if narrative fades.
  3. Tier 4 (VEEV/IQV/TMO/DHR) mirrors the H2 "beaten-down AI SW" thesis from sector_outlook_2026_h2. If SW catches a bid on AI-monetization pivot, life-sciences tools should follow.
  4. Tier 5 (ISRG/ABT/MDT) is NOT a chase. Deep drawdowns — wait for structure to build.
  5. Bio hedge role: today's tape (2026-07-02) showed MRNA +7% while SMH βˆ’3% — biotech decouples on semi-crash days. See memory feedback_bio_hedge_on_semi_drop.md.

Tactical Allocation Sketch (Bio/Drug slice only)

25%  Tier 3 AI Dx     (ILMN + GH + NTRA + TEM) β€” highest track record
20%  Tier 1 AI-native (MRNA + ABSI + ABCL) β€” moonshot exposure, half-size
20%  Tier 2 Big Pharma AI (LLY + MRK + JNJ + AMGN) β€” catch-up if narrative extends
20%  Tier 4 Beaten-down (VEEV + TMO + DHR) β€” rerating candidates
10%  Cash            (opportunistic reload if Tier 3 corrects 20%+)
 5%  Wildcards      (CRSP + TWST + ADPT reload) β€” small size

Caveats

← Back to Market Calendar